Arca
Skip to content

Achondroplasia

Drug research and approvals for achondroplasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 9 studies of achondroplasia are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 3 approved and 4 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 9
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 3
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 9 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 11; search them all in Canada trials
May 12, 2026A phase 3, randomized, double-blind, active controlled, multicenter trial investigating the efficacy and safety of dual therapy with once-weekly navepegritide…NAVEPEGRITIDE (TRANSCON CNP) / LONAPEGSOMATROPINAscendis PharmaPending
Jan 22, 2026A multicenter, randomized, operationally seamless phase 2/3 study to evaluate the efficacy and safety of bmn 333 versus vosoritide in children with…BMN 333 / VOSORITIDE (BMN 111)BioMarin PharmaceuticalOngoing
Nov 21, 2025A phase 2, multicenter, double-blind, randomized, placebo-controlled trial, evaluating safety, tolerability, and efficacy of subcutaneous doses of transcon cnp…NAVEPEGRITIDE (TRANSCON CNP)Ascendis PharmaOngoing
Jul 28, 2025Phase 2b, randomized, double-blind, placebo-controlled clinical trial, preceded by a single ascending dose portion and a phase 2 open-label portion, to…INFIGRATINIBQED THERAPEUTICS, INC.Ongoing
May 28, 2025A phase 2b, multicenter, double-blind, randomized, placebo-controlled trial evaluating efficacy and safety of subcutaneous doses of navepegritide administered…NAVEPEGRITIDE (TRANSCON CNP)Ascendis PharmaPending
Mar 19, 2025A multicenter, phase 2, dose-escalation/dose-expansion study of tyra-300 in children with achondroplasia with open growth plates: beach301DABOGRATINIB (TYRA-300)TYRA BIOSCIENCES INC.Ongoing
Nov 20, 2024Attach: a phase 2, multicenter, long-term, open label extension trial evaluating safety, tolerability, and efficacy of subcutaneous doses of transcon cnp…NAVEPEGRITIDEAscendis PharmaOngoing
Nov 27, 2023A phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children 3 to <18 years of…INFIGRATINIBQED THERAPEUTICS, INC.Closed
Jan 3, 2023A phase 2b, multicenter, double-blind, randomized, placebo-controlled trial evaluating efficacy and safety of subcutaneous doses of transcon cnp administered…TRANSCON CNPAscendis PharmaClosed
Oct 20, 2022Phase 2, open-label, long-term, extension (ole) study of infigratinib, an fgfr 1-3-selective tyrosine kinase inhibitor, in children with achondroplasia: propel…INFIGRATINIB (BGJ398, BBP-831)QED THERAPEUTICS, INC.Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first
Feb 27, 2026Yuviwelto increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphysesAscendis Pharma Growth Disorders A/SApproved
Oct 20, 2023Voxzogoto increase linear growth in pediatric patients with achondroplasia with open epiphysesBioMarin Pharmaceutical, Inc.Approved
Nov 19, 2021VoxzogoTo increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphysesBioMarin Pharmaceutical, Inc.Approved
Mar 16, 2026selective small molecular inhibitor of fibroblast growth…treatment of achondroplasiaAbbisko Therapeutics Co., Ltd.Designated
Jul 25, 2023Small molecule fibroblast growth factor receptor 3…Treatment of AchondroplasiaTyra BiosciencesDesignated
Jan 25, 2022Anti-fibroblast growth factor receptor 3 antigen-binding…Treatment of AchondroplasiaGenzyme Corporation, a Sanofi CompanyDesignated
Aug 12, 2021InfigratinibTreatment of achondroplasiaQED Therapeutics, Inc.Designated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Aug 26, 2021Voxzogovosoritide · orphanBioMarin International LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.